Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T17:07:08.761Z.
Calculation as of: 2026-10-06T17:07:08.761Z.
Quote observation: 2026-10-06T17:04:27.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b6268879a98e6c39cef7c3f9e2e80a63ea5355fd191f52e510f01db01fc6dd59
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Greenwich LifeSciences, Inc.
Market Cap
$243.66M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$242.31M
Free Cash Flow Yield
N/A
TTM Avg
1.67%
3Y Avg
1.64%
5Y Avg
2.28%
Market Cap
$240.38M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$241.78M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$244.06M
Free Cash Flow Yield
N/A
TTM Avg
12.33%
3Y Avg
12.33%
5Y Avg
12.33%
Market Cap
$240.34M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$246.31M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | $243.66M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.31M | N/A | 1.67% | 1.64% | 2.28% |
| Galectin Therapeutics Inc. (GALT)vs › | $240.38M | N/A | N/A | N/A | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $241.78M | N/A | N/A | N/A | N/A |
| Q32 Bio Inc. (QTTB)vs › | $244.06M | N/A | 12.33% | 12.33% | 12.33% |
| Invivyd, Inc. (IVVD)vs › | $240.52M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.34M | N/A | N/A | N/A | N/A |
| Quantum-Si incorporated (QSI)vs › | $246.31M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $238.61M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $237.27M | 16.93% | 15.02% | 15.02% | 15.02% |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
